bicalutamide has been researched along with benzofurans in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ha, YS; Jung, YS; Kim, IY; Kim, JH; Kim, WJ; Lee, GT | 1 |
| Li, F; Song, L; Tang, L; Tian, F; Wang, Z; Yang, J; Yu, Z | 1 |
2 other study(ies) available for bicalutamide and benzofurans
| Article | Year |
|---|---|
Bone morphogenetic protein-6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages.
Topics: Androgen Receptor Antagonists; Androgens; Anilides; Animals; Benzamides; Benzofurans; Bone Morphogenetic Protein 6; Cell Line, Tumor; Dihydrotestosterone; Humans; Interleukin-6; Lymphocytes, Tumor-Infiltrating; Macrophages; Male; Mice; Nitriles; Phenylthiohydantoin; Promoter Regions, Genetic; Prostatic Neoplasms, Castration-Resistant; Quinolines; Receptors, Androgen; Tosyl Compounds; Up-Regulation | 2013 |
Clinical research of Tashinone IIA combined with endocrine therapy in treating advanced-stage prostate cancer.
Topics: Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Hemoglobins; Humans; Leuprolide; Male; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Outcome | 2014 |